Angiopoietins in Diabetic Retinopathy: Current Understanding and Therapeutic Potential

Table 2

Overview of agents targeting the Ang/Tie2 pathway that are currently in clinical development.

Drug name	Developer	Target	Trial phase	Indication	Patients enrolled	Control	Primary outcome measure	Result
AKB-9778	Akebia Therapeutics	VE-PTP	IIb	DMO	167	Placebo	DRSS	Failed
REGN910-3	Regeneron	Ang2 and VEGF	II	DMO	301	Aflibercept	BCVA	Failed
RG-7716	Roche Genentech	Ang2 and VEGF	II	DMO	230	Low-dose ranibizumab	BCVA	Success

DRSS = diabetic retinopathy severity score; BCVA = best-corrected visual acuity.